A Comparison of 3-Year Follow-up of ZUMA-5 (Axicabtagene Ciloleucel) With SCHOLAR-5 in Relapsed/Refractory Follicular Lymphoma.
- DOI
- 10.1016/j.clml.2024.01.011
- Published
- 2024 May
- Container
- Clinical lymphoma, myeloma & leukemia
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.clml.2024.01.011,
title = {A Comparison of 3-Year Follow-up of ZUMA-5 (Axicabtagene Ciloleucel) With SCHOLAR-5 in Relapsed/Refractory Follicular Lymphoma.},
author = {Ghione P and Palomba ML and Ray MD and Limbrick-Oldfield EH and Owen J and Kanters S and Bobillo S and Ribiero MT and Jacobson CA and Neelapu SS and Ghesquieres H and Nahas M and Beygi S and Patel AR and Gribben JG},
year = {2024},
journal = {Clinical lymphoma, myeloma \& leukemia},
doi = {10.1016/j.clml.2024.01.011},
url = {https://doi.org/10.1016/j.clml.2024.01.011}
}RIS
TY - JOUR TI - A Comparison of 3-Year Follow-up of ZUMA-5 (Axicabtagene Ciloleucel) With SCHOLAR-5 in Relapsed/Refractory Follicular Lymphoma. AU - Ghione P AU - Palomba ML AU - Ray MD AU - Limbrick-Oldfield EH AU - Owen J AU - Kanters S AU - Bobillo S AU - Ribiero MT AU - Jacobson CA AU - Neelapu SS AU - Ghesquieres H AU - Nahas M AU - Beygi S AU - Patel AR AU - Gribben JG PY - 2024 JO - Clinical lymphoma, myeloma & leukemia DO - 10.1016/j.clml.2024.01.011 UR - https://doi.org/10.1016/j.clml.2024.01.011 ER -
APA
P, G., ML, P., MD, R., EH, L., J, O., S, K., S, B., MT, R., CA, J., SS, N., H, G., M, N., S, B., AR, P., & JG, G. (2024). A Comparison of 3-Year Follow-up of ZUMA-5 (Axicabtagene Ciloleucel) With SCHOLAR-5 in Relapsed/Refractory Follicular Lymphoma.. Clinical lymphoma, myeloma & leukemia. https://doi.org/10.1016/j.clml.2024.01.011
Source records
- pubmed · retrieved 2026-09-25T08:10:52.137Z